|
ANTICOAGULANT EFFECT IS INCREASED OF ORAL ANTICOAGULANTS
|
CONCOMITANT USE MAY CAUSE SEVERE CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION WITH ERYTHROMYCIN AND OTHER MACROLIDE ANTIBIOTICS MAY INCREASE DIGOXIN ABSORPTION IN PATIENTS WHO INACTIVATE DIGOXIN BY BACTERIAL METABOLISM IN THE LOWER INTESTINE, SO THAT DIGITALIS INTOXICATION MAY RESULT
|
CO-ADMINISTRATION WITH ERYTHROMYCIN AND OTHER MACROLIDE ANTIBIOTICS MAY INCREASE DIGOXIN ABSORPTION IN PATIENTS WHO INACTIVATE DIGOXIN BY BACTERIAL METABOLISM IN THE LOWER INTESTINE, SO THAT DIGITALIS INTOXICATION MAY RESULT
|
CONCURRENT USE WITH ASTEMIZOLE, REPORTED TO SIGNIFICANTLY ALTER THE METABOLISM OF ASTEMIZOLE; RARE CASES OF CARDIOVASCULAR ADVERSE EVENTS,LIKE PROLONGED QT INTERVAL, CARDIAC ARREST,TORSADE DE POINTES, AND VENTRICULAR ARRHYTHMIAS HAVE BEEN REPORTED
|
CONCURRENT USE OF ERYTHROMYCIN IN PATIENTS RECEIVING DRUGS METABOLIZED BY THE CYTOCHROME P450 SYSTEM MAY BE ASSOCIATED WITH ELEVATION IN SERUM LEVELS OF CARBAMAZEPINE
|
ERYTHROMYCIN DECREASES CLEARANCE OF BENZODIAZEPINES, THUS INCREASE THE PHARMACOLOGIC EFFECT OF THE DRUG SO THEIR DOSE SHOULD BE REDUCED TO 1/3
|
CONCURRENT USE OF ERYTHROMYCIN IN PATIENTS RECEIVING DRUGS METABOLIZED BY THE CYTOCHROME P450 SYSTEM MAY BE ASSOCIATED WITH ELEVATION IN SERUM LEVELS OF TACROLIMUS
|
HIGH LEVELS OF HMG-COA REDUCTASE INHIBITORY ACTIVITY IN PLASMA;LOVASTATIN IS METABOLIZED BY CYP3A4 ISOENZYME,CERTAIN AGENTS, SHARE THIS METABOLIC PATHWAY AND CAN RAISE THE PLASMA LEVELS OF LOVASTATIN & MAY INCREASE THE RISK OF MYOPATHY
|
HIGH LEVELS OF HMG-COA REDUCTASE INHIBITORY ACTIVITY IN PLASMA;LOVASTATIN IS METABOLIZED BY CYP3A4 ISOENZYME,CERTAIN AGENTS, SHARE THIS METABOLIC PATHWAY AND CAN RAISE THE PLASMA LEVELS OF LOVASTATIN & MAY INCREASE THE RISK OF MYOPATHY
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS TRICYCLIC ANTIDEPRESSANTS, MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS TRICYCLIC ANTIDEPRESSANTS, MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS TRICYCLIC ANTIDEPRESSANTS, MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS TRICYCLIC ANTIDEPRESSANTS, MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS TRICYCLIC ANTIDEPRESSANTS, MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS TRICYCLIC ANTIDEPRESSANTS, MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS TRICYCLIC ANTIDEPRESSANTS, MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS TRICYCLIC ANTIDEPRESSANTS, MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCURRENT USE OF ERYTHROMYCIN IN PATIENTS RECEIVING DRUGS METABOLIZED BY THE CYTOCHROME P450 SYSTEM MAY BE ASSOCIATED WITH ELEVATION IN SERUM LEVELS OF DISOPYRAMIDE
|
CONCURRENT USE OF ERYTHROMYCIN IN PATIENTS RECEIVING DRUGS METABOLIZED BY THE CYTOCHROME P450 SYSTEM MAY BE ASSOCIATED WITH ELEVATION IN SERUM LEVELS OF DIVALPROEX
|
CO-ADMINISTRATION HAS BEEN ASSOCIATED IN SOME PATIENTS WITH ACUTE ERGOT TOXICITY CHARACTERIZED BY SEVERE PERIPHERAL VASOSPASM AND DYSETHESIA
|
CO-ADMINISTRATION HAS BEEN ASSOCIATED IN SOME PATIENTS WITH ACUTE ERGOT TOXICITY CHARACTERIZED BY SEVERE PERIPHERAL VASOSPASM AND DYSETHESIA
|
CO-ADMINISTRATION HAS BEEN ASSOCIATED IN SOME PATIENTS WITH ACUTE ERGOT TOXICITY CHARACTERIZED BY SEVERE PERIPHERAL VASOSPASM AND DYSETHESIA
|
CO-ADMINISTRATION HAS BEEN ASSOCIATED IN SOME PATIENTS WITH ACUTE ERGOT TOXICITY CHARACTERIZED BY SEVERE PERIPHERAL VASOSPASM AND DYSETHESIA
|
CO-ADMINISTRATION HAS BEEN ASSOCIATED IN SOME PATIENTS WITH ACUTE ERGOT TOXICITY CHARACTERIZED BY SEVERE PERIPHERAL VASOSPASM AND DYSETHESIA
|
CO-ADMINISTRATION HAS BEEN ASSOCIATED IN SOME PATIENTS WITH ACUTE ERGOT TOXICITY CHARACTERIZED BY SEVERE PERIPHERAL VASOSPASM AND DYSETHESIA
|
CLOBAZAM CONCURRENT ADMINISTRATION WITH THE DRUG LEADS TO REDUCED CLEARANCE OF CLOBAZAM, HENCE THE DOSE SHOULD BE REDUCED TO ONE THIRD
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
INCREASES QT PROLONGATION WHICH COULD CAUSE ARRHYTHMIAS
|
INCREASES QT PROLONGATION WHICH COULD CAUSE ARRHYTHMIAS
|
INCREASES QT PROLONGATION WHICH COULD CAUSE ARRHYTHMIAS
|
BACTERIOSTATICS LIKE TETRACYCLINES MAY INTERFERE WITH BACTERICIDAL EFFECTS OF PENICILLIN ; THIS HAS BEEN DEMONSTRATED IN VITRO, HOWEVER, THE CLINICAL SIGNIFICANCE OF THE INTERACTION IS NOT WELL DOCUMENTED
|
BACTERIOSTATICS LIKE TETRACYCLINES MAY INTERFERE WITH BACTERICIDAL EFFECTS OF PENICILLIN ; THIS HAS BEEN DEMONSTRATED IN VITRO, HOWEVER, THE CLINICAL SIGNIFICANCE OF THE INTERACTION IS NOT WELL DOCUMENTED
|
BACTERIOSTATICS LIKE TETRACYCLINES MAY INTERFERE WITH BACTERICIDAL EFFECTS OF PENICILLIN ; THIS HAS BEEN DEMONSTRATED IN VITRO, HOWEVER, THE CLINICAL SIGNIFICANCE OF THE INTERACTION IS NOT WELL DOCUMENTED
|
BACTERIOSTATICS LIKE TETRACYCLINES MAY INTERFERE WITH BACTERICIDAL EFFECTS OF PENICILLIN ; THIS HAS BEEN DEMONSTRATED IN VITRO, HOWEVER, THE CLINICAL SIGNIFICANCE OF THE INTERACTION IS NOT WELL DOCUMENTED
|
BACTERIOSTATICS LIKE TETRACYCLINES MAY INTERFERE WITH BACTERICIDAL EFFECTS OF PENICILLIN ; THIS HAS BEEN DEMONSTRATED IN VITRO, HOWEVER, THE CLINICAL SIGNIFICANCE OF THE INTERACTION IS NOT WELL DOCUMENTED
|
BACTERIOSTATICS LIKE TETRACYCLINES MAY INTERFERE WITH BACTERICIDAL EFFECTS OF PENICILLIN ; THIS HAS BEEN DEMONSTRATED IN VITRO, HOWEVER, THE CLINICAL SIGNIFICANCE OF THE INTERACTION IS NOT WELL DOCUMENTED
|
BACTERIOSTATICS LIKE TETRACYCLINES MAY INTERFERE WITH BACTERICIDAL EFFECTS OF PENICILLIN ; THIS HAS BEEN DEMONSTRATED IN VITRO, HOWEVER, THE CLINICAL SIGNIFICANCE OF THE INTERACTION IS NOT WELL DOCUMENTED
|
BACTERIOSTATICS LIKE TETRACYCLINES MAY INTERFERE WITH BACTERICIDAL EFFECTS OF PENICILLIN ; THIS HAS BEEN DEMONSTRATED IN VITRO, HOWEVER, THE CLINICAL SIGNIFICANCE OF THE INTERACTION IS NOT WELL DOCUMENTED
|
BACTERIOSTATICS LIKE TETRACYCLINES MAY INTERFERE WITH BACTERICIDAL EFFECTS OF PENICILLIN ; THIS HAS BEEN DEMONSTRATED IN VITRO, HOWEVER, THE CLINICAL SIGNIFICANCE OF THE INTERACTION IS NOT WELL DOCUMENTED
|
BACTERIOSTATICS LIKE TETRACYCLINES MAY INTERFERE WITH BACTERICIDAL EFFECTS OF PENICILLIN ; THIS HAS BEEN DEMONSTRATED IN VITRO, HOWEVER, THE CLINICAL SIGNIFICANCE OF THE INTERACTION IS NOT WELL DOCUMENTED
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS INCLUDING VENTRICULAR TACHYCARDIA, FIBRILLATION, TORSADES DE POINTES & QT PROLONGATION
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS INCLUDING VENTRICULAR TACHYCARDIA, FIBRILLATION, TORSADES DE POINTES & QT PROLONGATION
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS INCLUDING VENTRICULAR TACHYCARDIA, FIBRILLATION, TORSADES DE POINTES & QT PROLONGATION
|
CO-ADMINISTRATION IN PATIENTS WHO ARE RECEIVING HIGH DOSES OF THEOPHYLLINE MAY BE ASSOCIATED WITH AN INCREASE IN SERUM THEOPHYLLINE LEVELS AND POTENTIAL THEOPHYLLINE TOXICITY
|
CO-ADMINISTRATION IN PATIENTS WHO ARE RECEIVING HIGH DOSES OF THEOPHYLLINE MAY BE ASSOCIATED WITH AN INCREASE IN SERUM THEOPHYLLINE LEVELS AND POTENTIAL THEOPHYLLINE TOXICITY
|
CO-ADMINISTRATION IN PATIENTS WHO ARE RECEIVING HIGH DOSES OF THEOPHYLLINE MAY BE ASSOCIATED WITH AN INCREASE IN SERUM THEOPHYLLINE LEVELS AND POTENTIAL THEOPHYLLINE TOXICITY
|
CO-ADMINISTRATION IN PATIENTS WHO ARE RECEIVING HIGH DOSES OF THEOPHYLLINE MAY BE ASSOCIATED WITH AN INCREASE IN SERUM THEOPHYLLINE LEVELS AND POTENTIAL THEOPHYLLINE TOXICITY
|
INCREASED CHANCES OF PROLONGED QT INTERVAL
|
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCURRENT USE OF ERYTHROMYCIN IN PATIENTS RECEIVING DRUGS METABOLIZED BY THE CYTOCHROME P450 SYSTEM MAY BE ASSOCIATED WITH ELEVATION IN SERUM LEVELS OF BROMOCRIPTINE
|
CONCURRENT USE OF ERYTHROMYCIN IN PATIENTS RECEIVING DRUGS METABOLIZED BY THE CYTOCHROME P450 SYSTEM MAY BE ASSOCIATED WITH ELEVATION IN SERUM LEVELS OF CYCLOSPORINE
|
CONCURRENT USE OF ERYTHROMYCIN IN PATIENTS RECEIVING DRUGS METABOLIZED BY THE CYTOCHROME P450 SYSTEM MAY BE ASSOCIATED WITH ELEVATION IN SERUM LEVELS OF PHENYTOIN
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
BENZODIAZEPINES / DIAZEPAM CLEARANCE IS REDUCED BY CO-ADMINISTRATION; HENCE THE DOSE OF DIAZEPAM IS REDUCED BY ONE THIRD
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS BETA BLOCKERS, MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS BETA BLOCKERS, MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS BETA BLOCKERS, MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS TRICYCLIC ANTIDEPRESSANTS, MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS TRICYCLIC ANTIDEPRESSANTS, MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS TRICYCLIC ANTIDEPRESSANTS, MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS TRICYCLIC ANTIDEPRESSANTS, MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS ANTIHISTAMINE , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS ANTIHISTAMINE , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS ANTIHISTAMINE , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION MAY CAUSE PROLONGATION OF Q-T INTERVAL LEADING TO INCREASED RISK OF VENTRICULAR ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION MAY CAUSE PROLONGATION OF Q-T INTERVAL LEADING TO INCREASED RISK OF VENTRICULAR ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION MAY CAUSE PROLONGATION OF Q-T INTERVAL LEADING TO INCREASED RISK OF VENTRICULAR ARRHYTHMIAS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION MAY CAUSE PROLONGATION OF Q-T INTERVAL LEADING TO INCREASED RISK OF VENTRICULAR ARRHYTHMIAS
|
SEROTONIN SYNDROME MAY OCCUR DUE TO INCREASED PLASMA LEVELS OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS
|
SEROTONIN SYNDROME MAY OCCUR DUE TO INCREASED PLASMA LEVELS OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS
|
SEROTONIN SYNDROME MAY OCCUR DUE TO INCREASED PLASMA LEVELS OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS
|
SEROTONIN SYNDROME MAY OCCUR DUE TO INCREASED PLASMA LEVELS OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS
|
SEROTONIN SYNDROME MAY OCCUR DUE TO INCREASED PLASMA LEVELS OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS
|
CO-ADMINISTRATION OF OTHER DRUGS KNOWN TO ALTER CARDIAC CONDUCTION, SUCH AS PHENOTHIAZINES , MIGHT ALSO CONTRIBUTE TO A PROLONGATION OF THE QTC INTERVAL & INCREASED RISK OF CARDIAC ARRHYTHMIAS
|